[Treatment of familial erythermalgia with the association of lidocaine and mexiletine]
- PMID: 12843854
[Treatment of familial erythermalgia with the association of lidocaine and mexiletine]
Abstract
Introduction: Erythermalgia is a rare acrosyndrome characterized by reddening of the skin, local increase heat and pain. The disease is frequently resistant to treatment. Recently, Kuhnert et al. presented very favorable results using a combination of lidocaine and mexiletine. We used this treatment in 4 patients suffering from familial erythermalgia.
Observations: In a family exhibiting severe familial erythermalgia involving 5 members over 3 generations, we treated 4 patients aged 41, 39, 19 and 15 years. In these patients, the erythermalgia known since early childhood, progressed in the form of multiple flares (6 to 7/day) during the day and at night, lasting several hours and often accompanied by headaches. The impact of the disease on their quality of life was major. Only cold-water baths provided temporary relief, obliging them to live with their "feet in cold water". After they had been informed of the modalities of treatment and in the absence of any contraindication, notably cardiologic, 200 mg (100 mg in the youngest patient) of lidocaine were infused in 4 hours in a single intravenous injection on the first day. Mixelitine was introduced on the second day at the dose of 600 mg in 3 oral intakes (200 mg in the youngest patient). The painful paroxistic symptomatology rapidly improved and the flares had disappeared on the 3dr day, thus permitting the progressive reduction in analgesics and major improvement in quality of life. This beneficial effect persisted with oral mexiletine alone, 2 years after the infusion of lidocaine in the first patient treated (and one year after in the other patients).
Comments: Primary familial erythermalgia is highly resistant to treatment. The combined action of lidocain and mexiletine, usually well tolerated (class IB antiarrythmic), blocks the sodium channels. The mechanism of action of their analgesic effect is peripheral or central or even mixed. This benefit warrants confirmation in other forms of erythermalgia.
Similar articles
-
Primary erythromelalgia in a child responding to intravenous lidocaine and oral mexiletine treatment.Pediatrics. 2005 Apr;115(4):e504-7. doi: 10.1542/peds.2004-1395. Epub 2005 Mar 1. Pediatrics. 2005. PMID: 15741349
-
[Familial erythermalgia treated with pizotifen].Ann Dermatol Venereol. 1995;122(11-12):777-9. Ann Dermatol Venereol. 1995. PMID: 8729824 Review. French.
-
Mexiletine-responsive erythromelalgia due to a new Na(v)1.7 mutation showing use-dependent current fall-off.Exp Neurol. 2009 Apr;216(2):383-9. doi: 10.1016/j.expneurol.2008.12.012. Epub 2008 Dec 31. Exp Neurol. 2009. PMID: 19162012
-
The effects of mexiletine on excitability properties of human median motor axons.Clin Neurophysiol. 2005 Feb;116(2):284-9. doi: 10.1016/j.clinph.2004.08.014. Clin Neurophysiol. 2005. PMID: 15661106 Clinical Trial.
-
[Classification of erythermalgia].J Mal Vasc. 1996;21(2):80-3. J Mal Vasc. 1996. PMID: 8755186 Review. French.
Cited by
-
Pain disorders and erythromelalgia caused by voltage-gated sodium channel mutations.Curr Neurol Neurosci Rep. 2012 Feb;12(1):76-83. doi: 10.1007/s11910-011-0233-8. Curr Neurol Neurosci Rep. 2012. PMID: 21984269 Review.
-
Ion channel pharmacology.Neurotherapeutics. 2007 Apr;4(2):184-98. doi: 10.1016/j.nurt.2007.01.013. Neurotherapeutics. 2007. PMID: 17395128 Review.
-
Mutations in sodium-channel gene SCN9A cause a spectrum of human genetic pain disorders.J Clin Invest. 2007 Dec;117(12):3603-9. doi: 10.1172/JCI33297. J Clin Invest. 2007. PMID: 18060017 Free PMC article. Review.
-
Selective Targeting of Nav1.7 with Engineered Spider Venom-Based Peptides.Channels (Austin). 2021 Dec;15(1):179-193. doi: 10.1080/19336950.2020.1860382. Channels (Austin). 2021. PMID: 33427574 Free PMC article. Review.
-
Mexiletine as a treatment for primary erythromelalgia: normalization of biophysical properties of mutant L858F NaV 1.7 sodium channels.Br J Pharmacol. 2014 Oct;171(19):4455-63. doi: 10.1111/bph.12788. Epub 2014 Aug 29. Br J Pharmacol. 2014. PMID: 24866741 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources